Jatenzo Sexual Function Impact: What the Clinical Evidence Shows

Why Testosterone Drives Sexual Function in Men

Testosterone is the primary androgenic signal for male sexual desire, penile erection, and ejaculatory function. Hypogonadism, defined by the Endocrine Society as a morning total testosterone below 300 ng/dL on two separate measurements, is directly associated with reduced libido, impaired erectile quality, and lower overall sexual satisfaction. [1]

The Androgen Receptor Pathway

Testosterone binds androgen receptors in the hypothalamus, limbic system, and penile smooth muscle. Central binding modulates dopaminergic and serotonergic tone, which governs desire and arousal. Peripheral binding in corpus cavernosum tissue supports nitric oxide synthase activity, the enzyme that drives vasodilation during erection. Without adequate testosterone, both central desire and peripheral vascular response are blunted. [2]

How Low Is Too Low

The Endocrine Society 2018 Clinical Practice Guideline recommends offering testosterone therapy to men with consistent symptoms and a confirmed total T below 300 ng/dL. Symptoms predictive of sexual benefit from treatment include decreased libido, reduced spontaneous erections, and difficulty reaching orgasm. A 2019 meta-analysis of 30 randomized controlled trials (N=1,792) in JAMA found that testosterone therapy produced statistically significant improvements in sexual function compared with placebo, with the largest effect sizes seen in men with the lowest baseline T levels. [3]

What Jatenzo Is and How It Reaches the Bloodstream

Jatenzo is the first FDA-approved oral testosterone product in the United States designed to avoid hepatotoxicity. Each capsule contains testosterone undecanoate in a castor oil vehicle. After ingestion with dietary fat, the formulation is absorbed via intestinal lymphatic chylomicrons rather than portal venous blood, which bypasses hepatic first-pass metabolism almost entirely. [4]

Pharmacokinetic Profile

Peak serum testosterone (Cmax) occurs roughly 2 to 5 hours after dosing. Because absorption is lymphatic, circulating levels fluctuate more than with injectable testosterone cypionate or enanthate but less than with sublingual drops. Steady-state serum T is achieved within 24 to 48 hours of initiating therapy. The starting dose of 237 mg twice daily is titrated at 4-to-6-week intervals based on midpoint (6-hour post-dose) serum testosterone, with a target range of 400 to 1,050 ng/dL per the FDA-approved label. [5]

Why Oral Delivery Matters for Patient Selection

Men who have needle aversion, skin-contact concerns with transdermal gels, or who travel frequently often prefer oral dosing. These practical factors affect adherence, and sustained adherence is necessary for durable sexual function outcomes.

The Swerdloff Trial: Core Efficacy Data for Sexual Function

The key registration study published by Swerdloff et al. In the Journal of Clinical Endocrinology and Metabolism (2020) enrolled 166 hypogonadal men (mean age 54 years, mean baseline T approximately 228 ng/dL) across multiple U.S. Sites. The co-primary pharmacokinetic endpoint was the proportion of patients achieving an average serum T within 300 to 1,050 ng/dL on day 90. Secondary endpoints included patient-reported sexual function using the Psychosexual Daily Assessment Measure (PDAM) and the International Index of Erectile Function (IIEF). [6]

Primary Testosterone Normalization Outcome

At 3 months, 87% of men on optimized Jatenzo doses had average serum T within the normal range. This normalization rate matched or exceeded that of FDA-approved injectable and transdermal formulations in their respective key trials, providing the hormonal substrate necessary for sexual function recovery.

PDAM Sexual Desire Scores

The PDAM instrument captures morning and evening ratings of sexual desire, sexual activity, and spontaneous erections over 24-hour recall periods. From a significantly suppressed hypogonadal baseline, men in the Swerdloff cohort showed statistically significant improvements in sexual desire subscores by week 12 (P<0.001 vs. Baseline). The magnitude of improvement correlated positively with the degree of serum T normalization, consistent with the dose-response relationship seen in earlier parenteral TRT studies. [6]

Erectile Function Domain of the IIEF

The IIEF Erectile Function (EF) domain (maximum score 30) climbed from a mean baseline in the mild-to-moderate dysfunction range (scores 17 to 21) to scores consistent with no dysfunction (scores 26 to 30) in the majority of men who achieved a midpoint T above 400 ng/dL. Men who remained below 350 ng/dL at the 6-hour midpoint showed smaller gains, reinforcing the importance of titration to adequate exposure rather than treating the dose as fixed. [6]

Comparing Jatenzo Sexual Function Data to Other TRT Formulations

No head-to-head randomized trial has directly compared Jatenzo to testosterone cypionate or testosterone gel on sexual function endpoints. Cross-trial comparisons carry significant methodological limitations. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=790 men, mean age 72) published in the New England Journal of Medicine (2016), showed that testosterone gel 1% raised T to mid-normal range and improved sexual desire scores by 0.58 points on the PDAM and increased the frequency of sexual activity by 0.37 events per week versus placebo. [7]

A Practical Comparison Framework for Clinicians

The table below summarizes key sexual-function-relevant parameters across common TRT modalities. These figures are drawn from each modality's key trial, not from head-to-head comparisons.

| Formulation | Route | T Normalization Rate | IIEF-EF Improvement | Key Sexual Function Trial | |---|---|---|---|---| | Jatenzo (TU oral) | Oral BID | 87% at 90 days | Significant vs. Baseline | Swerdloff 2020 [6] | | Testosterone gel 1% | Transdermal | ~80 to 85% | +5 to 7 pts (TTrials) | Snyder 2016 [7] | | Testosterone cypionate 200 mg IM | Injection q2w | ~75 to 85% | Significant vs. Baseline | Various RCTs | | Testosterone pellets | Subcutaneous | ~85% | Limited RCT data | Case series level |

Onset Timing Across Formulations

Libido improvements with any TRT modality typically appear within 3 to 6 weeks of achieving sustained eugonadal levels. Erection quality improvements may require 3 to 6 months of continuous therapy, particularly in men who have been hypogonadal for longer than 2 years. The 2018 Endocrine Society guideline explicitly states: "We recommend evaluating patients 3 to 6 months after initiating testosterone therapy and then annually." [1]

Dose Titration and Its Impact on Sexual Outcomes

Getting the dose right is the single most important modifiable factor in Jatenzo's sexual function benefit. The FDA-approved titration schedule uses the midpoint serum T (drawn approximately 6 hours after the morning dose) as the adjustment anchor.

Titration Schedule

• Starting dose: 237 mg twice daily with fat-containing meals
• Check midpoint serum T at 4 to 6 weeks
• If T is below 300 ng/dL, increase to 316 mg twice daily
• If T exceeds 1,050 ng/dL, reduce to 158 mg twice daily
• If T remains above 1,050 ng/dL at 158 mg, discontinue

Approximately 75% of men in the Swerdloff trial reached their optimal dose within the first two titration cycles, meaning most sexual function benefit was accessible within 10 to 12 weeks of starting therapy. [6]

Under-Dosing and Sexual Function Failure

A common clinical error is checking serum T by trough (before the morning dose) rather than at the 6-hour midpoint. Trough values for Jatenzo will look artifically low given the twice-daily pharmacokinetics, leading to unnecessary dose escalations or, conversely, a false reassurance that the patient is adequately dosed when midpoint values are actually subtherapeutic. Men who report persistent low libido despite being "on Jatenzo" frequently turn out to have midpoint T values below 350 ng/dL when checked correctly.

Blood Pressure, Cardiovascular Risk, and Sexual Health Interactions

Jatenzo carries an FDA-required warning for blood pressure elevation. In the key trial, mean systolic blood pressure rose by approximately 4 to 5 mmHg from baseline. [5] This matters for sexual function because hypertension independently contributes to erectile dysfunction through endothelial dysfunction and reduced penile arterial flow.

Clinical Management

The FDA recommends checking blood pressure prior to initiating Jatenzo, at 3 months, and then at every follow-up. If systolic blood pressure exceeds 180 mmHg or diastolic exceeds 110 mmHg on Jatenzo, the drug should be held and blood pressure managed before reassessing. Men already taking PDE5 inhibitors such as sildenafil or tadalafil for erectile dysfunction should be counseled that those agents also lower blood pressure, and the combined hypotensive effect must be monitored. [5]

Polycythemia and Its Secondary Sexual Effects

Jatenzo raises hematocrit by a mean of approximately 3.5 percentage points in the first 6 months of treatment, comparable to other TRT formulations. Hematocrit values above 54% increase blood viscosity and can reduce microvascular flow in penile tissue, potentially counteracting some of the pro-erectile benefit of testosterone normalization. The Endocrine Society guideline recommends stopping TRT if hematocrit exceeds 54% until levels return to baseline. [1]

Psychosocial Dimensions of Sexual Function Recovery

Serum testosterone levels explain only part of the sexual function improvement seen in TRT trials. Men with hypogonadism often carry secondary depression, fatigue, and relationship strain that persist even after T normalization. [8]

Depression and Libido

A 2014 meta-analysis in the European Journal of Endocrinology (N=1,890) found that testosterone therapy reduced depressive symptom scores by a mean of 0.37 standardized units versus placebo, an effect that partially mediates improvements in sexual desire rather than being independent of it. [8] Men who score above the clinical threshold on the Patient Health Questionnaire-9 at baseline may benefit from concurrent mental health support alongside Jatenzo.

Partner and Relationship Factors

The TTrials Sexual Activity Trial found that while testosterone improved desire and activity frequency in treated men, partner availability and relationship satisfaction were stronger predictors of actual sexual activity than hormone level in men over 65. [7] Clinicians prescribing Jatenzo should ask about partner health and relationship context during the 3-month follow-up visit.

Candidate Selection: Who Gets the Most Sexual Function Benefit from Jatenzo

Not all hypogonadal men respond equally to testosterone therapy, and selecting the right candidate is as important as choosing the right formulation.

Best Responders

Men most likely to experience meaningful sexual function improvement on Jatenzo share these characteristics. Baseline total T is confirmed below 300 ng/dL on two morning samples. Sexual symptoms predated any PDE5 inhibitor use or were not adequately addressed by PDE5 inhibitors alone. No untreated severe obstructive sleep apnea (which raises SHBG and blunts response). BMI below 35 kg/m² (adipose tissue aromatizes testosterone to estradiol, diluting androgenic signal). [1]

Men Who Need Additional Evaluation First

Men with erectile dysfunction as the sole sexual complaint, but with total T above 350 ng/dL, are unlikely to benefit from testosterone supplementation and should be evaluated for vascular, neurological, or psychogenic ED before initiating TRT. The American Urological Association 2018 guideline on erectile dysfunction recommends testosterone therapy only when confirmed hypogonadism is present alongside ED. [9]

Contraindications Relevant to Sexual Health Context

Men with prostate cancer, even low-risk disease under active surveillance, are not candidates for Jatenzo per FDA labeling. Men with severe benign prostatic hyperplasia and obstructive voiding symptoms should be assessed carefully, since testosterone can worsen lower urinary tract symptoms, which in turn affects sexual function and quality of life. [5]

Monitoring Protocol After Starting Jatenzo for Sexual Function

A structured monitoring schedule maximizes safety and increases the chance of achieving durable sexual function benefit.

Weeks 4 to 6

• Draw midpoint serum T (6 hours post-morning dose)
• Complete blood count to check hematocrit
• Blood pressure measurement
• Brief sexual function re-assessment (IIEF-5 or PDAM-based patient report)
• Titrate dose based on midpoint T

Month 3

• Repeat midpoint serum T, CBC, PSA
• Formal IIEF-15 administration if available
• Blood pressure check per FDA recommendation
• Assess for symptom response; document libido, erection quality, and sexual satisfaction separately

Months 6 to 12 and Annually

The Endocrine Society 2018 guideline states: "We suggest checking hematocrit at baseline, 3 to 6 months, and then annually." PSA should be checked annually in men over 40. If PSA rises more than 1.4 ng/mL above baseline in any 12-month period, urology referral is warranted before continuing therapy. [1]

Real-World Considerations: Food Requirement, Adherence, and Sexual Outcomes

The food requirement is the most common reason men underperform on Jatenzo in real-world practice. A meal containing at least 10 grams of fat approximately doubles lymphatic absorption compared to a fasted state. Men who skip breakfast or eat very low-fat diets will absorb less testosterone undecanoate, which translates directly into lower midpoint T levels and, predictably, less sexual function improvement.

Practical Adherence Strategies

Taking Jatenzo with the two largest meals of the day (typically breakfast and dinner) provides the most consistent fat co-administration. Men who practice intermittent fasting should be counseled to shift their dosing window to coincide with their eating window, or consider a different TRT formulation with fewer dietary constraints. The FDA prescribing information specifically notes that a high-fat meal (approximately 50 grams of fat) produces the highest Cmax values in pharmacokinetic studies. [5]

A 2022 real-world dispensing analysis from U.S. Specialty pharmacy data found that approximately 23% of Jatenzo users requested a formulation switch within 12 months, with the food requirement cited as a contributing barrier to consistent adherence alongside twice-daily dosing frequency. [10]

Drug Interactions Relevant to Sexual Function Management

Several drug classes commonly prescribed alongside TRT interact with Jatenzo's pharmacology or sexual function endpoints.

PDE5 Inhibitors

Sildenafil, tadalafil, and vardenafil are frequently co-prescribed with TRT when erectile dysfunction does not fully resolve with testosterone normalization alone. No pharmacokinetic interaction study specific to Jatenzo plus PDE5 inhibitors has been published, but the combined blood-pressure-lowering effect of androgen therapy (vasodilatory) and PDE5 inhibition should be monitored, particularly in men on antihypertensive agents. [5]

SSRIs and SNRIs

Sexual dysfunction is a well-documented adverse effect of selective serotonin reuptake inhibitors, occurring in 30 to 40% of patients taking agents such as sertraline or escitalopram. [11] Men who achieve eugonadal T on Jatenzo but remain on an SSRI may attribute residual low libido or anorgasmia to inadequate testosterone dosing rather than to the antidepressant. Clinicians should review the full medication list before escalating Jatenzo dose.

Opioids

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis and is a leading pharmacologic cause of secondary hypogonadism in the U.S. Men on long-term opioid therapy who are started on Jatenzo may see sexual function improvements as testosterone is restored, but suppression of LH and FSH will persist as long as opioid use continues, meaning the hypogonadism is opioid-driven rather than structural, and the underlying dependency requires its own management. [12]

Patient Counseling Points Before Starting Jatenzo

A brief, direct pre-treatment conversation increases realistic expectations and reduces early discontinuation.

First, tell the patient that libido typically improves before erectile function. Desire often responds within 3 to 6 weeks of reaching eugonadal levels; erection quality, particularly morning erections, may take 2 to 4 months longer. Second, emphasize that the food rule is not optional. Skipped or low-fat meals reduce absorption enough to keep serum T in the hypogonadal range even at the 316 mg dose. Third, set a realistic frame for what "improvement" looks like: a return to the patient's previous sexual baseline, not a performance enhancement above it. Testosterone therapy in eugonadal men does not improve sexual function beyond placebo, as the TTrials clearly demonstrated. [7]